HUS1700033I1 - Illékony alkilezõszerek stabilizált készítményei és eljárások azok alkalmazására - Google Patents

Illékony alkilezõszerek stabilizált készítményei és eljárások azok alkalmazására

Info

Publication number
HUS1700033I1
HUS1700033I1 HUS1700033C HUS1700033C HUS1700033I1 HU S1700033 I1 HUS1700033 I1 HU S1700033I1 HU S1700033 C HUS1700033 C HU S1700033C HU S1700033 C HUS1700033 C HU S1700033C HU S1700033 I1 HUS1700033 I1 HU S1700033I1
Authority
HU
Hungary
Prior art keywords
methods
alkylating agents
stabilized preparations
volatile alkylating
volatile
Prior art date
Application number
HUS1700033C
Other languages
English (en)
Hungarian (hu)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36971840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1700033(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of HUS1700033I1 publication Critical patent/HUS1700033I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUS1700033C 2005-03-14 2017-08-11 Illékony alkilezõszerek stabilizált készítményei és eljárások azok alkalmazására HUS1700033I1 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66135605P 2005-03-14 2005-03-14
US75112805P 2005-12-16 2005-12-16
US11/369,305 US7872050B2 (en) 2005-03-14 2006-03-07 Stabilized compositions of volatile alkylating agents and methods of using thereof
PCT/US2006/009060 WO2006099385A2 (en) 2005-03-14 2006-03-14 Stabilized compositions of volatile alkylating agents and methods of using thereof
EP06738150A EP1858864B1 (en) 2005-03-14 2006-03-14 Stabilized compositions of volatile alkylating agents and methods of using thereof

Publications (1)

Publication Number Publication Date
HUS1700033I1 true HUS1700033I1 (hu) 2017-09-28

Family

ID=36971840

Family Applications (1)

Application Number Title Priority Date Filing Date
HUS1700033C HUS1700033I1 (hu) 2005-03-14 2017-08-11 Illékony alkilezõszerek stabilizált készítményei és eljárások azok alkalmazására

Country Status (19)

Country Link
US (7) US7872050B2 (https=)
EP (1) EP1858864B1 (https=)
JP (2) JP5236457B2 (https=)
KR (1) KR101168252B1 (https=)
CN (1) CN101175735B (https=)
AU (1) AU2006223076B2 (https=)
CA (1) CA2600468C (https=)
CY (2) CY1113305T1 (https=)
DK (1) DK1858864T3 (https=)
ES (1) ES2388744T3 (https=)
FR (1) FR17C1029I2 (https=)
HU (1) HUS1700033I1 (https=)
LT (1) LTC1858864I2 (https=)
LU (1) LUC00033I2 (https=)
NZ (3) NZ599001A (https=)
PL (1) PL1858864T3 (https=)
PT (1) PT1858864E (https=)
SI (1) SI1858864T1 (https=)
WO (1) WO2006099385A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
LT3494960T (lt) * 2008-03-27 2021-02-25 Helsinn Healthcare Sa Stabilizuotos alkilinimo agentų kompozicijos ir jų naudojimo būdai
EP2326306A1 (en) * 2008-09-25 2011-06-01 Cephalon, Inc. Liquid formulations of bendamustine
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
US8545892B2 (en) * 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
PL3158991T3 (pl) 2010-01-28 2021-09-27 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
WO2011109248A1 (en) 2010-03-02 2011-09-09 Hapten Pharmaceuticals, Llc Effective sensitizing dose of a gelled immunomodulating topical composition
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
WO2013009800A2 (en) * 2011-07-11 2013-01-17 Ceptaris Therapeutics, Inc. Compositions of alkylating agents and methods of treating skin disorders therewith
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
KR20140075693A (ko) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20140005148A1 (en) * 2012-06-29 2014-01-02 Coldstream Laboratories Inc. Stable liquid formulations of nitrogen mustards
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US20150320774A1 (en) 2014-05-09 2015-11-12 AuroMedics Pharma LLC Formulations of cyclophosphamide liquid concentrate
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3302423B1 (en) 2015-06-04 2022-05-25 Crititech, Inc. Particle production system and particle collection device
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
BR112018069628A2 (pt) 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
EP3615145B1 (en) 2017-06-09 2024-05-15 Crititech, Inc. Compositions for use in the treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
JP6584588B2 (ja) 2017-12-22 2019-10-02 レオキシン・エルエルシー セルライトの治療のための組成物及び方法
WO2019231499A1 (en) * 2018-05-31 2019-12-05 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for treatment of cancer
KR102914853B1 (ko) 2021-10-08 2026-01-20 기초과학연구원 항암 치료 개선을 위한 2-클로로-n,n-디에틸에틸아민 염산염의 용도

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US79492A (en) * 1868-06-30 Improvement in weae-plates foe, boots and shoes
US312290A (en) * 1885-02-17 James g
US157545A (en) * 1874-12-08 Improvement in car-couplings
US4083692A (en) 1970-06-04 1978-04-11 The United States Of America As Represented By The Secretary Of The Army Detection and estimation of microquantities of alkylating agents
US3767792A (en) 1971-07-02 1973-10-23 Stanley Drug Products Inc Method for controlling the toxicity of drug products
US3904766A (en) 1973-06-19 1975-09-09 Scott Eugene J Van Treatment of psoriasis
US4206222A (en) 1977-06-23 1980-06-03 Societe Civile Particuliere De Brevets Suffren Method for preparing a substance having properties against collagen diseases and products obtained
EP0250486A4 (en) 1986-01-03 1988-05-25 Univ Melbourne MELPHALAN DERIVATIVES.
US4863910A (en) 1986-05-20 1989-09-05 Takeo Takayanagi Complexes of AZO compounds and/or their salts and an antitumor agent and a method for reducing the growth of tumors
US4725438A (en) * 1986-05-29 1988-02-16 Leazer Billie S Aloe vera ointment
IE60588B1 (en) 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
US5326790A (en) 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
US4853388A (en) 1987-05-15 1989-08-01 Pearlman Dale L Method for treating psoriasis with cytotoxic agents
US5051363A (en) 1987-06-26 1991-09-24 University Of Pennsylvania Method for modifying the toxicity of DNA reactive cross-linking agents to cells
US5229422A (en) 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
GB8727157D0 (en) 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
US5098717A (en) 1987-12-09 1992-03-24 Thames Pharmacal Co., Inc. Method of treatment for pruritus
US4888354A (en) 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DE4005911C1 (https=) * 1990-02-24 1991-04-25 Gmn Georg Mueller Nuernberg Ag, 8500 Nuernberg, De
US4949641A (en) 1990-03-05 1990-08-21 The United States Of America As Represented By The Secretary Of The Army Method of safely detoxifying mustard gases
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5820872A (en) 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
WO1995003028A1 (en) * 1993-07-23 1995-02-02 Morris Herstein Cosmetic, skin-renewal stimulating composition with long-term irritation control
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
GB9501052D0 (en) 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
US6551611B2 (en) 1995-09-28 2003-04-22 Schering Aktiengesellschaft Hormone replacement therapy method
US5744460A (en) 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6124108A (en) 1996-05-15 2000-09-26 The United States Of America As Represented By The Secretary Of The Army Protein biomarker for mustard chemical injury
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
DK0923941T3 (da) 1996-06-27 2006-09-18 Chugai Pharmaceutical Co Ltd Midler mod myelom der skal anvendes sammen med nitrogensennepantitumormidler
US6255502B1 (en) 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6753155B1 (en) 1997-05-13 2004-06-22 The United States Of America As Represented By The Secretary Of The Army Protein biomarker for mustard chemical injury
CA2294247C (en) 1997-07-01 2004-10-26 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
EP1051490A2 (en) 1998-01-30 2000-11-15 Cold Spring Harbor Laboratory Modulation of cell proliferation, methods and reagents
GB9805868D0 (en) 1998-03-20 1998-05-13 Zeneca Ltd Anti-tumour agents
US20060079492A1 (en) 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
US6329148B1 (en) 1999-02-16 2001-12-11 The Board Of Trustees Of The Leland Stanford University Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
US6017902A (en) 1999-02-25 2000-01-25 Brookhaven Science Associates Boron containing amino acid compounds and methods for their use
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
US20020146692A1 (en) 2000-01-21 2002-10-10 Victoria Yamazaki Methods and materials relating to G protein-coupled receptor-like polypeptides and polynucleotides
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20030215471A1 (en) 2001-01-31 2003-11-20 Wilmott James M. Surfactant free topical compositions and method for rapid preparation thereof
US7547673B2 (en) 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
US20030083321A1 (en) 2001-09-25 2003-05-01 Lerner David S. Composition and method for minimizing or avoiding adverse effects of vesicants
US20030082229A1 (en) 2001-11-01 2003-05-01 Board Of Regents, The University Of Texas Systems Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
US6885492B2 (en) * 2001-11-08 2005-04-26 Imaginative Optics, Inc. Spatial light modulator apparatus
CA2504665C (en) 2002-11-12 2012-12-18 Jewish General Hospital Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
WO2004054501A2 (en) 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
AU2003291872A1 (en) 2002-12-04 2004-06-23 Inrs (Institut National De Recherche Scientifique) An exopolysaccharides delivery system for active molecules
US20050039228A1 (en) 2003-06-19 2005-02-17 The Samuel Roberts Noble Foundation Methods and compositions for analysis of plant gene function
WO2005007129A2 (en) 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
US20070287719A1 (en) 2005-03-11 2007-12-13 Pfizer Inc Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
US20120157545A1 (en) 2005-03-14 2012-06-21 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US20110039943A1 (en) 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20060281720A1 (en) * 2005-06-08 2006-12-14 Loria Roger M 5-Androstenediol As An Inhibitor of Gliomas
LT3494960T (lt) 2008-03-27 2021-02-25 Helsinn Healthcare Sa Stabilizuotos alkilinimo agentų kompozicijos ir jų naudojimo būdai
WO2013009800A2 (en) 2011-07-11 2013-01-17 Ceptaris Therapeutics, Inc. Compositions of alkylating agents and methods of treating skin disorders therewith

Also Published As

Publication number Publication date
WO2006099385A2 (en) 2006-09-21
CA2600468A1 (en) 2006-09-21
US8501819B2 (en) 2013-08-06
CY1113305T1 (el) 2016-04-13
NZ589188A (en) 2012-06-29
US20060205694A1 (en) 2006-09-14
US20080194699A1 (en) 2008-08-14
US20140155491A1 (en) 2014-06-05
US20140194526A1 (en) 2014-07-10
CN101175735A (zh) 2008-05-07
CY2017027I2 (el) 2018-04-04
LUC00033I2 (https=) 2017-10-11
CY2017027I1 (el) 2018-04-04
US20110065803A1 (en) 2011-03-17
PT1858864E (pt) 2012-09-25
AU2006223076A1 (en) 2006-09-21
AU2006223076B2 (en) 2012-02-09
US8664278B2 (en) 2014-03-04
US20130310461A1 (en) 2013-11-21
JP2013091643A (ja) 2013-05-16
PL1858864T3 (pl) 2012-11-30
CN101175735B (zh) 2014-04-23
JP2008533152A (ja) 2008-08-21
FR17C1029I2 (fr) 2019-10-18
US8450375B2 (en) 2013-05-28
US7838564B2 (en) 2010-11-23
HK1119675A1 (en) 2009-03-13
FR17C1029I1 (fr) 2017-09-29
EP1858864A2 (en) 2007-11-28
WO2006099385A8 (en) 2008-03-13
LTC1858864I2 (lt) 2018-06-25
WO2006099385A3 (en) 2007-04-19
LUC00033I1 (https=) 2017-08-10
NZ599001A (en) 2013-03-28
US7872050B2 (en) 2011-01-18
JP5671514B2 (ja) 2015-02-18
US20100041767A1 (en) 2010-02-18
EP1858864B1 (en) 2012-07-04
US9382191B2 (en) 2016-07-05
CA2600468C (en) 2015-05-05
DK1858864T3 (da) 2012-09-10
JP5236457B2 (ja) 2013-07-17
ES2388744T3 (es) 2012-10-18
NZ561268A (en) 2010-12-24
KR20070120163A (ko) 2007-12-21
SI1858864T1 (sl) 2012-10-30
LTPA2017026I1 (lt) 2017-09-11
KR101168252B1 (ko) 2012-07-30
EP1858864A4 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
HUS1700033I1 (hu) Illékony alkilezõszerek stabilizált készítményei és eljárások azok alkalmazására
IL191759A (en) Ganaxolone formulations and methods for the making and use thereof
IL257622B (en) Methods and compositions for the treatment of persistent infections
IL195491A (en) Pharmaceutical compositions of tmc278 and processes for their preparation
EP1909831A4 (en) SELF-BUFFING PROTEIN FORMULATIONS
IL184735A0 (en) Pharmaceutical formulations and methods of use
IL188732A (en) Use of ibuprofen and famotidine in the preparation of medicaments
HUS1900046I1 (hu) Triazinonokat és vasat tartalmazó készítmények
EP1895838A4 (en) COMPOSITIONS AND METHODS
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
FR2889449B1 (fr) Preparations implantables
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
PL1971366T3 (pl) Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
HUE061246T2 (hu) HFO-1234ze és HFC-134a tartalmú készítmények
MA28489B1 (fr) Preparations pharmaceutiques
EP1954571A4 (en) RETRACTABLE POLYLACTIC ACID FILMS AND METHODS OF MOLDING THEM
BRPI0813457A2 (pt) Composto de organoenxofre contendo halogênio e uso do mesmo
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
HUE032901T2 (hu) Készítmények és eljárások csontnövekedés elõidézésére és csontvesztés gátlására
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
IL181819A (en) Use of benzo-fused compounds for the preparation of a medicament and methods making use of said compounds
HRP20150320T1 (xx) Formulacije i metode za lijeäśenje amiloidoze
HUE043668T2 (hu) Szemészeti készítmények és alkalmazásuk